Patent 9051542

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Active provider: Google · gemini-2.5-flash

PTAB activity (1)

AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.

  • IPR2025-01194IPRfiled Jun 26, 2025vs. Sarepta Therapeutics, Inc. et al.Discretionary Denial

Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.

Cases on file (3)

Group view →

Specific litigation cases in our database that name US patent 9051542. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

✓ Generated

Known litigation involving US patent 9051542 includes the following cases:

District Court Litigation:

  1. Genzyme Corp. v. Sarepta Therapeutics, Inc., and Sarepta Therapeutics Three, LLC

    • Plaintiff(s): Genzyme Corp. (a wholly owned subsidiary of Sanofi)
    • Defendant(s): Sarepta Therapeutics, Inc., and Sarepta Therapeutics Three, LLC
    • Jurisdiction: District Court for the District of Delaware
    • Case Number: 1:24-cv-00882
    • Filing Date: July 26, 2024
    • Outcome/Current Status: The case is ongoing and has been assigned to Judge Andrews. Genzyme alleges that Sarepta's manufacture and sale of Elevidys® infringes US patent 9051542 and US patent 7704721. Genzyme is seeking judgments of infringement (including deliberate and willful infringement), compensatory damages (including treble damages), and reasonable attorneys' fees, costs, and expenses.

  2. Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.

    • Plaintiff(s): Genzyme Corporation et al.
    • Defendant(s): Novartis Gene Therapies, Inc. et al.
    • Jurisdiction: District Court for the District of Delaware
    • Case Number: 1:21-cv-01736
    • Filing Date: December 10, 2021
    • Outcome/Current Status: This is an ongoing litigation. Claims 1 and 2 of US patent 9051542 were disclaimed by the Patent Owner to streamline issues, with only claims 5 and 6 being asserted for infringement in this case.

Patent Trial and Appeal Board (PTAB) Cases:

  1. IPR2023-00608

    • Petitioner(s): Novartis Gene Therapies, Inc. & Novartis Pharmaceuticals Corporation
    • Patent Owner: Genzyme Corporation
    • Challenged Claims: Claims 5 and 6 of US patent 9051542. (Initially 1, 2, 5, and 6 were challenged, but claims 1 and 2 were disclaimed).
    • Filing Date: The petition was filed in 2023, with a decision entered on August 30, 2023.
    • Outcome/Current Status: Petition denied. The Patent Trial and Appeal Board determined that the Petitioner had not demonstrated a reasonable likelihood of prevailing with respect to any challenged claim.

  2. IPR2023-00609

    • Petitioner(s): Novartis Gene Therapies, Inc. & Novartis Pharmaceuticals Corporation
    • Patent Owner: Genzyme Corporation
    • Challenged Claims: Claims of US patent 9051542, specifically claims 5 and 6 were challenged on other grounds.
    • Filing Date: The petition was filed in 2023.
    • Outcome/Current Status: Not Instituted - Merits.

  3. IPR2025-01194

    • Petitioner(s): Not specified in available data.
    • Patent Owner: Not specified in available data.
    • Challenged Claims: Not specified in available data.
    • Filing Date: The case was filed in 2025.
    • Outcome/Current Status: Not Instituted - Procedural.

Generated 5/18/2026, 12:47:08 PM